NICE gives final thumbs up to ThromboGenics/Alcon's Jetrea
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has given Alcon/ThromboGenics' Jetrea (ocriplasmin) a formal and final nod. Today's new guidance makes Jetrea the first drug to be made available on the National Health Service for patients with vitreomacular traction
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.